Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026)

Area of Science:

• Urology
• Oncology
• Medical Guidelines

Background:

• The American Urological Association (AUA) previously published a guideline for localized prostate cancer in 2022.
• Continuous evaluation of medical literature is essential for guideline relevance.

Purpose of the Study:

• To update the 2022 AUA Guideline on the evaluation and management of clinically localized prostate cancer.
• To incorporate new evidence and provide a revised clinical framework.

Main Methods:

• A comprehensive literature review was conducted in 2025, examining studies published between July 1, 2021, and December 5, 2024.
• 29 studies were reviewed for full-text inclusion, along with 8 studies on artificial intelligence in disease management.
• Guideline statements were updated based on the evidence and consensus from the expert panel.

Main Results:

• The updated guideline provides evidence- and consensus-based statements for localized prostate cancer.
• Key updates include revised recommendations on imaging modalities.
• New information on shared decision-making (SDM) and disease management strategies are incorporated.

Conclusions:

• This 2026 Guideline Amendment offers revised insights into localized prostate cancer evaluation and management.
• Specific updates address imaging, shared decision-making, radiation treatment, and disease management.
• Ongoing review is necessary due to the rapid evolution of diagnostic and treatment options.